We report that a small adaptor protein, SH3BGRL, is upregulated in the majority of breast cancer patients, especially elevated in those with metastatic relapse, indicating it as a marker for the poor prognosis of breast cancer
2021
Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation
Key concepts
Scholarcy highlights
- Metastatic recurrence is still a major challenge in breast cancer treatment, but the underlying mechanisms remain unclear
- We report that a small adaptor protein, SH3BGRL, is upregulated in the majority of breast cancer patients, especially elevated in those with metastatic relapse, indicating it as a marker for the poor prognosis of breast cancer
- Clinical analysis validates that SH3BGRL expression is negatively correlated with profilin 1 and PTEN levels, but positively to the activations of AKT, NF-kB, and WNT signaling pathways in breast patient tissues
- Our results suggest that SH3BGRL is a valuable prognostic factor and a potential therapeutic target for preventing breast cancer progression and metastasis
Need more features? Save interactive summary cards to your Scholarcy Library.